[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-32156":3,"doc-seo-32156":28},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":19,"is_deleted":4,"is_public":20,"is_downloadable":20,"audit_status":20,"page_count":21,"language":22,"language_code":23,"table_of_contents":24,"faqs":25,"seo_title":13,"seo_description":14,"update_tm":26,"read_time":27},32156,16904993612988,"Olivia Brown","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",7,"Healthcare","Cabotegravir plus Rilpivirine for Persons with HIV and Adherence Challenges","Long-acting injectable antiretroviral therapy (ART) strategies have limited randomized evidence for people with HIV who struggle to adhere to oral medication. An open-label, randomized LATITUDE trial enrolled participants with inadequate ART adherence and compared standard oral care with monthly injections of long-acting cabotegravir plus rilpivirine, with or without oral lead-in. By week 48, regimen failure occurred less often with cabotegravir–rilpivirine than with standard care, while adverse-event incidence and resistance development were similar across groups.","cbCaijycq2njMdBC","https://ap.wps.com/l/cbCaijycq2njMdBC","pdf",737171,3,1,14,"English","en","# Background\n# Methods\n# Results\n# Conclusions","[{\"question\":\"What population was studied in the LATITUDE trial?\",\"answer\":\"Participants had HIV and inadequate adherence to ART, including persistent HIV-1 RNA \\u003e200 copies per milliliter or loss to follow-up.\"},{\"question\":\"How was the cabotegravir–rilpivirine regimen compared with standard care?\",\"answer\":\"After an adherence-support step, eligible participants were randomized to continue standard oral ART or switch to monthly long-acting cabotegravir plus rilpivirine, with or without oral lead-in therapy.\"},{\"question\":\"What was the primary outcome and main finding by week 48?\",\"answer\":\"Regimen failure (confirmed virologic failure or treatment discontinuation during step 2) was lower with cabotegravir–rilpivirine (22.8%) than with standard care (41.2%), with a statistically significant difference.\"}]",1780952463,35,{"code":4,"msg":29,"data":30},"ok",{"site_id":31,"language":23,"slug":32,"title":13,"keywords":33,"description":14,"schema_data":34,"social_meta":85,"head_meta":87,"extra_data":89,"updated_unix":26},105,"cabotegravir-plus-rilpivirine-for-persons-with-hiv-and-adherence-challenges","",{"@graph":35,"@context":84},[36,52,67],{"@type":37,"itemListElement":38},"BreadcrumbList",[39,43,47,49],{"item":40,"name":41,"@type":42,"position":20},"https://docshare.wps.com","Home","ListItem",{"item":44,"name":45,"@type":42,"position":46},"https://docshare.wps.com/document/","Document",2,{"item":48,"name":12,"@type":42,"position":19},"https://docshare.wps.com/document/healthcare/",{"item":50,"name":13,"@type":42,"position":51},"https://docshare.wps.com/document/cabotegravir-plus-rilpivirine-for-persons-with-hiv-and-adherence-challenges/32156/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":61,"encodingFormat":59,"isAccessibleForFree":62,"interactionStatistic":63},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":40,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-06-13","2026-06-08",true,{"@type":64,"interactionType":65,"userInteractionCount":19},"InteractionCounter",{"@type":66},"ViewAction",{"@type":68,"mainEntity":69},"FAQPage",[70,76,80],{"name":71,"@type":72,"acceptedAnswer":73},"What population was studied in the LATITUDE trial?","Question",{"text":74,"@type":75},"Participants had HIV and inadequate adherence to ART, including persistent HIV-1 RNA >200 copies per milliliter or loss to follow-up.","Answer",{"name":77,"@type":72,"acceptedAnswer":78},"How was the cabotegravir–rilpivirine regimen compared with standard care?",{"text":79,"@type":75},"After an adherence-support step, eligible participants were randomized to continue standard oral ART or switch to monthly long-acting cabotegravir plus rilpivirine, with or without oral lead-in therapy.",{"name":81,"@type":72,"acceptedAnswer":82},"What was the primary outcome and main finding by week 48?",{"text":83,"@type":75},"Regimen failure (confirmed virologic failure or treatment discontinuation during step 2) was lower with cabotegravir–rilpivirine (22.8%) than with standard care (41.2%), with a statistically significant difference.","https://schema.org",{"og:url":50,"og:type":86,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":88,"canonical":50},"index,follow",{"doc_id":7,"site_id":31}]